Intermediate for Carfilzomib. Carfilzomib (trade name: Kyprolis) is an anti-cancer drug acting as a selective proteasome inhibitor. Carfilzomib has been approved by the U.S Food and Drug Administration on July 20, 2012.
Product Name: (S)-4-(tert-Butoxycarbonylamino)-2,6-dimethyl-1-hepten-3-one
CAS Number: 247068-81-1
Molecular Weight:  255.3564
Molecular Formula:  C14H25NO3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.